Ardais Corporation Appoints Donald B. Hawthorne As President And Chief Executive Officer 
10/19/2005 5:10:46 PM

LEXINGTON, Mass., Nov. 17 /PRNewswire/ -- Ardais Corporation, a leading clinical genomics company that provides products and services for drug discovery, appointed Donald B. Hawthorne President and Chief Executive Officer and member of the Company's Board of Directors. Mr. Hawthorne has held leadership positions in the healthcare industry for over 20 years, and has extensive experience in growing emerging companies. He replaces Gregory D. Phelps, who left Ardais to pursue other opportunities.

William Mills, Partner, Advent International; member, Board of Directors, Ardais Corporation, stated, "The application of human disease to drug discovery, known as clinical genomics, is a rapidly emerging field. Ardais has already made a significant impact in this area through collaborations with pharmaceutical and biotech partners, and we are excited about additional near- term business opportunities, which we are developing."

Since 1999, Mr. Hawthorne has been a contract operating partner to the healthcare venture capital community, providing general management and strategic advisory services. Formerly, he was a Partner and Chief Financial Officer at Ampersand Ventures, a private equity firm. Mr. Hawthorne holds an MBA from the Stanford Graduate School of Business.

About Ardais Corporation

Ardais Corporation, a privately held clinical genomics company, is dedicated to enhancing and accelerating biomedical research by applying actual human disease as the discovery model in pharmaceutical research and development. The Ardais BIGR(R) System encompasses a unique and growing biorepository, called the BIGR(R) Library, of more than 180,000 Research- Quality tissue samples and associated clinical data from more than 14,000 donors, representing a broad diversity of disease states. The Company recently announced the availability of its BIGR(R) Biospecimen Management System (BMS), a comprehensive set of services and licenses that enable biomedical researchers in pharmaceutical, biotechnology and academic medical research institutions to collect, annotate, manage and distribute their human biological material resources. For more information, please visit

Contacts: Christine Mackenzie Communications Associate Ardais Corporation (781) 274-6420 Francesca T. DeVellis Vice President Feinstein Kean Healthcare (617) 577-8110

Ardais Corporation

CONTACT: Christine Mackenzie, Communications Associate of ArdaisCorporation, +1-781-274-6420; or Francesca T. DeVellis, Vice President ofFeinstein Kean Healthcare, +1-617-577-8110